Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

This study has suspended participant recruitment.
(No inclusion)
Sponsor:
Collaborators:
GELCAB
GLIMCE
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
GRUPO ARAGONÉS
Information provided by:
PETHEMA Foundation
ClinicalTrials.gov Identifier:
NCT00662948
First received: April 8, 2008
Last updated: October 27, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: October 2014
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)